MTEM(Delisted)
Molecular Templates·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 4
Significant Revenue Decline
Revenue Beats Expectation
Price Hits New Low
Price Hits 52-week Low
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MTEM
Molecular Templates, Inc.
A company that developing therapeutics for cancer including solid tumors
9301 Amberglen Blvd, Suite 100, Austin TX 78729
--
Molecular Templates, Inc., was incorporated in Delaware on October 17, 2001. The company is a biotechnology company focused on drug discovery and development for severe tissue hypoxia in the microenvironment of solid tumors and the bone marrow of patients with hematological malignancies. In June 2005, after conducting clinical trials in Europe, the company established a wholly-owned subsidiary in the UK — THLD Ltd. On February 3, 2012, the company obtained a global license and co-development agreement with Merck KGaA of Darmstadt, Germany, to jointly develop, produce and sell TH-302 (a small molecule drug for tissue hypoxia in Germany). Under the terms of the agreement, Merck obtains co-development rights and worldwide sales rights, and licenses the company to co-sell TH-302 in the United States. The company is a biotechnology company that uses its expertise in tumor microenvironment to discover and develop therapeutic agents that selectively target tumor cells to provide treatment for cancer patients. The company's advanced clinical investigational small molecule, TH-302, is currently being evaluated in two important third clinical trials and multiple early clinical trials. The Company has a global license and co-development agreement with Merck KGaA for TH-302 and co-sales in the United States.
Company Financials
EPS
MTEM has released its 2024 Q2 earnings. EPS was reported at -1.23, versus the expected -1.44, beating expectations. The chart below visualizes how MTEM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MTEM has released its 2024 Q2 earnings report, with revenue of 572.00K, reflecting a YoY change of -91.67%, and net profit of -8.10M, showing a YoY change of 25.50%. The Sankey diagram below clearly presents MTEM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
